IL214435A0 - Foxm1 peptides and vaccines containing the same - Google Patents

Foxm1 peptides and vaccines containing the same

Info

Publication number
IL214435A0
IL214435A0 IL214435A IL21443511A IL214435A0 IL 214435 A0 IL214435 A0 IL 214435A0 IL 214435 A IL214435 A IL 214435A IL 21443511 A IL21443511 A IL 21443511A IL 214435 A0 IL214435 A0 IL 214435A0
Authority
IL
Israel
Prior art keywords
same
vaccines containing
foxm1 peptides
foxm1
peptides
Prior art date
Application number
IL214435A
Other languages
English (en)
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL214435A0 publication Critical patent/IL214435A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL214435A 2009-02-18 2011-08-03 Foxm1 peptides and vaccines containing the same IL214435A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15340809P 2009-02-18 2009-02-18
PCT/JP2010/001005 WO2010095428A1 (en) 2009-02-18 2010-02-17 Foxm1 peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
IL214435A0 true IL214435A0 (en) 2011-09-27

Family

ID=42633716

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214435A IL214435A0 (en) 2009-02-18 2011-08-03 Foxm1 peptides and vaccines containing the same

Country Status (15)

Country Link
US (1) US8617562B2 (enExample)
EP (1) EP2408912B1 (enExample)
JP (1) JP5728717B2 (enExample)
KR (1) KR101713586B1 (enExample)
CN (1) CN102405285B (enExample)
BR (1) BRPI1008887A2 (enExample)
CA (1) CA2752560C (enExample)
DK (1) DK2408912T3 (enExample)
ES (1) ES2618896T3 (enExample)
IL (1) IL214435A0 (enExample)
MX (1) MX2011008763A (enExample)
RU (1) RU2560431C2 (enExample)
SG (1) SG173751A1 (enExample)
TW (1) TWI469791B (enExample)
WO (1) WO2010095428A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101543624B1 (ko) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
GB201410686D0 (en) * 2014-06-16 2014-07-30 Immunocore Ltd & Adaptimmune Ltd Peptides
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
CN105524159B (zh) * 2015-11-16 2021-04-09 西南交通大学 具有癌细胞选择性杀伤和迁移抑制作用的多肽分子与用途
CN105999227B (zh) * 2016-08-12 2019-08-06 湖南大学 FOXM1蛋白氮端（1-234 aa）的表达及其用途
IL265834B2 (en) 2016-10-07 2023-03-01 Univ Texas hla-restricted vgll1 peptides and their use
CN111787930B (zh) * 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
ES2935702T3 (es) * 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
CN109055327B (zh) * 2018-07-23 2021-04-06 浙江工业大学 醛酮还原酶突变体及其应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN115803084A (zh) 2020-05-21 2023-03-14 得克萨斯大学体系董事会 具有vgll1特异性的t细胞受体和其用途
CN114591400B (zh) * 2022-03-29 2022-10-21 西南交通大学 一组靶向FoxM1-DBD多肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
EP0846761A1 (en) 1996-12-09 1998-06-10 Introgene B.V. A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2002099076A2 (en) 2001-06-04 2002-12-12 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants ii
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1462456A4 (en) 2001-12-10 2005-09-21 Greenpeptide Co Ltd TUMOR ANTIGENS
AU2003272247A1 (en) * 2002-08-28 2004-03-19 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
WO2005090991A1 (en) 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
CN1703524B (zh) * 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
AU2005213464A1 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
EP2343384A3 (en) 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006141208A (ja) 2004-11-16 2006-06-08 Univ Of Tokushima 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
EP1806413A1 (en) 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
JP2009536516A (ja) 2006-04-20 2009-10-15 オンコセラピー・サイエンス株式会社 肺癌の治療標的としてのＮＭＵ−ＧＨＳＲ１ｂ／ＮＴＳＲ１発癌シグナル伝達経路
KR101543624B1 (ko) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
ES2537323T3 (es) 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
KR101744514B1 (ko) 2009-03-18 2017-06-08 온코세라피 사이언스 가부시키가이샤 Ｎｅｉｌ3 펩티드 및 이를 포함하는 백신

Also Published As

Publication number Publication date
CA2752560A1 (en) 2010-08-26
KR101713586B1 (ko) 2017-03-08
EP2408912A4 (en) 2013-04-17
MX2011008763A (es) 2011-09-09
DK2408912T3 (en) 2017-03-20
EP2408912A1 (en) 2012-01-25
KR20110117241A (ko) 2011-10-26
US8617562B2 (en) 2013-12-31
SG173751A1 (en) 2011-09-29
AU2010216980A1 (en) 2011-08-25
JP2012517799A (ja) 2012-08-09
RU2011138160A (ru) 2013-03-27
RU2560431C2 (ru) 2015-08-20
TW201032821A (en) 2010-09-16
BRPI1008887A2 (pt) 2016-03-01
WO2010095428A1 (en) 2010-08-26
CN102405285B (zh) 2015-04-22
CN102405285A (zh) 2012-04-04
ES2618896T3 (es) 2017-06-22
US20120156231A1 (en) 2012-06-21
TWI469791B (zh) 2015-01-21
JP5728717B2 (ja) 2015-06-03
CA2752560C (en) 2017-01-24
EP2408912B1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
SG173751A1 (en) Foxm1 peptides and vaccines containing the same
IL203899A (en) Foxm1-derived peptide compounds
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
IL229926A0 (en) 3neil peptides and vaccines containing them
IL219976A0 (en) Imp-3 oligopeptides and vaccines including the same
IL209869A0 (en) Iqgap3 epitope peptides and vaccines containing the same
ZA201207416B (en) Cdca5 peptides and vaccines including the same
IL228995A0 (en) b5sema peptides and components containing them
ZA201303886B (en) Tomm34 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
IL216211A0 (en) Cdc45l peptides and vaccines including the same
EP2430039A4 (en) TTK-PEPTIDES AND VACCINES CONTAINING THEM
GB0818065D0 (en) Immunogenic peptides and uses thereof
IL221474A0 (en) Hjurp peptides and vaccines including the same
IL213318A0 (en) C1orf59 peptides and vaccines including the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
IL219927A0 (en) Mybl2 peptides and vaccines containing the same
IL220146A0 (en) Tmem22 peptides and vaccines including the same
ZA201207342B (en) Ect2 peptides and vaccines including the same
IL225553A0 (en) 54orf18c peptides and vaccines containing them
IL225552A0 (en) wdhd1 peptides and vaccines containing them
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
HK1166088A (zh) C6orf167肽及包含它的疫苗
HK1186213A (en) Ttll4 peptides and vaccines containing the same
HK1166096A (en) Vangl1 peptides and vaccines including the same